secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001193125-26-127931
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

MiNK Therapeutics confirms active discussions for combination trials and strategic investments
--------------------------------------------------------------------------------

- Company is in active discussions with multiple parties for potential combination trials of agenT-797.
- Discussions also include potential strategic minority investments in MiNK.
- No binding arrangements have been publicly disclosed; no assurance of final agreements.
- Clarification issued in response to third-party postings regarding potential trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000119312526127931/0001193125-26-127931-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000119312526127931/inkt-20260327.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-127931

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer